资料显示，联检(江苏)科技股份有限公司位于江苏省常州市木梳路10号，成立日期2003年3月19日，上 市日期2022年8月31日，公司主营业务涉及建设综合技术服务(建筑工程质量检测与咨询、建筑物(构筑 物)结构检测及其改造(加固)、地下空间建设安全咨询与服务等)以及研发、生产、销售新型建筑材料。 主营业务收入构成为：检验检测服务70.09%，新型工程材料销售15.35%，特种工程专业服务14.31%， 城市安全0.25%。 截至6月30日，联检科技股东户数2.16万，较上期增加0.87%；人均流通股4892股，较上期减少0.86%。 2025年1月-6月，联检科技实现营业收入6.41亿元，同比增长7.93%；归母净利润2490.63万元，同比增长 37.75%。 分红方面，联检科技A股上市后累计派现2.53亿元。 责任编辑：小浪快报 9月11日，联检科技涨1.09%，成交额4847.75万元。两融数据显示，当日联检科技获融资买入额498.18 万元，融资偿还410.43万元，融资净买入87.75万元。截至9月11日，联检科技融资融券余额合计3706.59 万元。 融资方面，联检科技当日融资买入498.18万元 ...

9月1日，联检科技涨1.42%，成交额5048.34万元。两融数据显示，当日联检科技获融资买入额389.25万 元，融资偿还303.21万元，融资净买入86.04万元。截至9月1日，联检科技融资融券余额合计3486.86万 元。 融资方面，联检科技当日融资买入389.25万元。当前融资余额3486.86万元，占流通市值的1.61%，融资 余额低于近一年10%分位水平，处于低位。 分红方面，联检科技A股上市后累计派现2.53亿元。 责任编辑：小浪快报 融券方面，联检科技9月1日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，联检(江苏)科技股份有限公司位于江苏省常州市木梳路10号，成立日期2003年3月19日，上 市日期2022年8月31日，公司主营业务涉及建设综合技术服务(建筑工程质量检测与咨询、建筑物(构筑 物)结构检测及其改造(加固)、地下空间建设安全咨询与服务等)以及研发、生产、销售新型建筑材料。 截至6月30日，联检科技股东户数2.16万，较上期增加0.87%；人均流通股4892股， ...

Group 1 - The company, Lianjian Technology, announced on September 4 that it is pursuing an external growth strategy through precise mergers and acquisitions [2] - The company employs a three-dimensional merger strategy of "regional penetration + track expansion + qualification enhancement" to achieve targeted acquisitions [2] - The company prioritizes acquiring regional leaders, high-growth sectors driven by policy, and scarce qualification targets to quickly gain regional qualifications, customer resources, and laboratory networks [2] Group 2 - The company aims to seize high-growth sectors such as water conservancy, automotive, metrology calibration, and low carbon through mergers and acquisitions [2] - The company enhances its specialized qualifications and business capabilities in relevant fields through these acquisitions [2] - The company integrates resources using a "headquarters empowerment + regional autonomy" model, providing a digital management system and sharing customer resources while maintaining the stability of core teams [2]

Core Viewpoint - The company, Lianjian Technology, has extensive experience in the construction industry, focusing on building inspection, testing, and evaluation, and is well-equipped to provide integrated solutions for structural safety and quality enhancement [2]. Group 1: Company Expertise and Services - The company has qualifications for structural testing and can conduct various engineering quality inspections and structural evaluations, as well as real-time monitoring of building safety [2]. - It emphasizes the development of quality assurance and enhancement services for existing buildings and municipal infrastructure, particularly in urban renewal and renovation projects [2]. - The company has established research collaborations with institutions such as the Beijing Residential Building Design Institute and the Jiangsu Architectural Vocational and Technical College to study housing safety and insurance systems [2]. Group 2: Achievements and Recognition - The company has received several honors, including being recognized as an excellent unit in the Jiangsu construction engineering quality testing industry and a 3A-rated enterprise for evaluation and consulting [2]. - It has participated in numerous judicial evaluations and has provided professional testing and evaluation reports for various cases, gaining significant project experience across different building types [2]. - Since 2022, the company has been involved in safety inspections of self-built houses across multiple provinces, receiving consistent recognition from local governments for its contributions [2].

Group 1: Company Operations and Acquisitions - The company has officially entered the automotive testing field through the acquisition of Guanbiao Testing, which provides comprehensive testing services for automobiles and components, enhancing its capabilities in various areas such as material, environmental reliability, electrical performance, and electromagnetic compatibility (EMC) [2] - Guanbiao Testing has obtained third-party testing qualifications from major automotive manufacturers including Geely, Chery, and NIO, expanding its recognition in both traditional and new energy vehicle sectors [2] - The company employs a three-dimensional acquisition strategy focusing on "regional penetration + track expansion + qualification enhancement" to achieve precise mergers and acquisitions, aiming to quickly gain regional qualifications and customer resources [2] Group 2: International Expansion - The company is advancing its global layout in phases, initially focusing on countries along the "Belt and Road" by establishing localized teams to provide tailored testing and certification services [2] - In the mid-term, the company plans to build R&D centers in mature technical standard markets such as Europe and the U.S. to absorb advanced experiences and promote mutual recognition of qualifications [2] - As of now, the company has established regional offices in countries like Vietnam, Thailand, and Indonesia, creating a grid service system that covers "Belt and Road" countries [2] Group 3: Building Safety and Research Initiatives - The company has extensive experience in building safety inspections and has established research collaborations with various institutions to study housing safety management and insurance systems [3] - It has received multiple honors, including being recognized as an excellent unit in construction quality testing in Jiangsu Province and a 3A-rated consulting enterprise [3] - The company has participated in nationwide safety inspections for self-built houses since 2022, covering a wide range of provinces and receiving recognition from local governments [3]

从解禁市值来看，3家公司解禁股数超亿元。福田汽车、益诺思、速达股份解禁市值居前，解禁市值分 别为39.86亿元、25.14亿元、10.79亿元。 从解禁股数占总股本比例来看，3家公司解禁比例超10%。益诺思、速达股份、福田汽车解禁比例居 前，解禁比例分别为44.33%、34.71%、18.04%。 从解禁量来看，3家公司解禁股数超千万股。福田汽车、益诺思、速达股份解禁量居前，解禁股数分别 为14.29亿股、6249.8万股、2638.28万股。 每经AI快讯，Wind数据显示，周三（9月3日），共有6家公司限售股解禁，合计解禁量为15.19亿股，按 最新收盘价计算，合计解禁市值为76.15亿元。 ...

Group 1 - The core viewpoint of the article is that Lianjian Technology (301115) is experiencing stable operational development, as indicated by its financial performance in the first half of 2025 [1] - In the first half of 2025, the company achieved a total operating revenue of 641 million yuan, representing a year-on-year growth of 7.93% [1] - The net profit attributable to the parent company for the same period was 24.91 million yuan, showing a significant year-on-year increase of 37.75% [1]

Core Viewpoint - On September 1, a total of 10 listed companies had their restricted shares unlocked, with a total market value of approximately 5.496 billion yuan [1] Summary by Category Restricted Shares Unlocking - The specific details of the restricted shares unlocking are as follows: - Qingxin Environment (002573): 8.2485 million shares from equity incentive restrictions - Jianke Co., Ltd. (301115): 16.1265 million shares from pre-issue restrictions - Naer Co., Ltd. (002825): 1.2133 million shares from equity incentive restrictions - Guanghetong (300638): 0.5158 million shares from equity incentive restrictions - Liren Technology (001259): 51.66 million shares from pre-issue restrictions - Xutian Salt Industry (600929): 5.295 million shares from equity incentive restrictions - Hanyi Co., Ltd. (301270): 25.9384 million shares from pre-issue restrictions - Wuzhou Special Paper (605007): 1.1687 million shares from equity incentive restrictions - Wufangzhai (603237): 52.9543 million shares from pre-issue restrictions - Aotwei (688516): 16.1989 million shares [1]

Investment Rating - The report provides a positive outlook on the MASH non-invasive diagnosis technology, suggesting it could accelerate new drug development in the pharmaceutical and biotechnology sector [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 0.65% from August 25 to August 29, underperforming compared to the Wind All A index (1.9%) and the CSI 300 index (2.71%). Only the medical research outsourcing (4.9%) and other biological products (0.14%) sectors saw gains, while in vitro diagnostics (-4.12%), raw materials (-3.34%), and vaccines (-0.59%) faced significant declines [2][7]. - The FDA has accepted the proposal for using VCTE-LSM as a reasonable alternative endpoint for clinical trials in adults with MASH and moderate to advanced fibrosis. This non-invasive method is expected to enhance patient compliance and could lead to a surge in drug development in the MASH area within the next two to three years [2][13]. - The report emphasizes the potential for domestic companies in China to leverage their cost advantages and forward-looking strategies in the field of non-invasive companion diagnostics, particularly in the MASH drug development competition [2]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance was notably weaker than the broader market indices, with specific sub-sectors like medical research outsourcing and other biological products showing resilience [7][8]. - Individual stocks such as Tianchen Medical (30.1%), Ailis (25.6%), and Maiwei Biotech-U (22.4%) performed well, while stocks like Lifang Pharmaceutical (-13.9%), Yuekang Pharmaceutical (-11.9%), and Kanghua Biotech (-11.1%) faced significant losses [10][12]. Industry News and Key Company Announcements - On August 28, Kangfang Biotech announced that its drug AK112 received approval for treating advanced non-squamous non-small cell lung cancer, with promising clinical trial results expected to be presented at an international conference [12]. - The report highlights various companies' financial performances, with notable revenue changes and profit margins, indicating a mixed outlook across the sector [16][17].

Core Viewpoint - The company, Lianjian Technology, has achieved significant growth in revenue and profit during the first half of 2025, demonstrating resilience and long-term growth potential in a challenging market environment [1][2]. Performance Summary - In the first half of 2025, Lianjian Technology reported a revenue of 641 million yuan, a year-on-year increase of 7.93%, and a net profit attributable to shareholders of 24.91 million yuan, up 37.75% compared to the same period last year, indicating improved profitability and operational efficiency [2]. Business Segment Analysis - The inspection and testing services segment generated 449 million yuan in revenue, reflecting a 14.55% year-on-year growth, showcasing the company's strong technical capabilities and market competitiveness in this area [3]. - The new engineering materials sales segment achieved revenue of 98.42 million yuan, growing by 8.44% year-on-year, supported by local operations in Southeast Asia [3]. - The special engineering services segment experienced slight revenue adjustments due to market conditions, but improved gross margins by 3.74 percentage points through refined project management [3]. Strategic Upgrade - Lianjian Technology underwent a significant brand upgrade, changing its name from "Jianke Co., Ltd." to "Lianjian Technology," marking a strategic shift towards becoming a global, comprehensive inspection and testing certification institution [4]. - The company is focusing on five core areas: quality, safety, intelligence, dual carbon, and urban-rural revitalization, expanding its service capabilities across various sectors beyond traditional construction testing [4]. Global Expansion - In the first half of 2025, Lianjian Technology's overseas revenue reached 27.77 million yuan, a 25.43% increase year-on-year, indicating successful implementation of its "going global" strategy [6]. - The company established a presence in Southeast Asia with new entities and partnerships, enhancing its local service capabilities and reducing operational costs [6][7]. - A recent acquisition of 60% of Shenzhen Zhongrentong Testing Technology Co., Ltd. will enhance the company's ability to provide seamless testing and certification services for global import and export enterprises [8]. Future Outlook - Lianjian Technology aims to become a leading global inspection and testing certification institution by focusing on domestic market expansion, accelerating international growth, and driving innovation in emerging fields [9].